Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Peanut allergy patch offers hope for kids

NCT ID NCT05424731

Disease control Sponsor: DBV Technologies Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program provides continued access to the Viaskin Peanut skin patch for children aged 2 and older with peanut allergy who previously completed a DBV712 study. The patch delivers a small amount of peanut protein through the skin each day to help desensitize the immune system. The goal is to reduce the risk of severe allergic reactions from accidental peanut exposure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Viaskin Peanut (DBV712) skin patch
What this could lead to
If successful, this program could help children with peanut allergy tolerate small amounts of peanut, reducing the risk of severe reactions from accidental exposure.
What could go wrong
This is an expanded access program, not a formal trial, so results are limited. The patch may cause skin irritation, and it does not cure the allergy—ongoing use is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 17 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participation is by invitation, limited to individuals completing clinical study V712-303 (PEOPLE), previous Expanded Access Program or a DBV clinical study initiated after 31-Jan-2022 * Male and females; ages ≥ 2 years old at Visit 1 or current or prior studies. * Negative urine pregnancy test for female participants of childbearing potential. Exclusion Criteria: * Early withdrawal from a DBV712 clinical study. * History of non-compliance during the primary clinical study or unable to follow the protocol requirements. * Generalized dermatologic disease extending widely on the skin. * History of intolerance or who developed hypersensitivity to excipients of the DBV712 patches.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peanut allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peanut allergy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Early Access Care, LLC

    AVAILABLE

    Madison, Connecticut, 06443, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.